1. HER2 studies look promising.
- Author
-
Meric-Bernstam F
- Subjects
- Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomedical Research methods, Boston, Clinical Trials, Phase II as Topic, Female, Germany, Humans, Italy, Molecular Targeted Therapy methods, Randomized Controlled Trials as Topic, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 genetics, Spain, Trastuzumab, Biomedical Research trends, Receptor, ErbB-2 physiology
- Published
- 2011
- Full Text
- View/download PDF